BRAF and neoplasm: addressed the heterogeneity of the mutations predicting the resistance to anti‐EGFR treatment (KRAS, NRAS, BRAF and/or PIK3CA) in the primary CRC tumours in the context of the proportion of neoplastic cells [12].